Are These Biotech Penny Stocks To ‘Buy’ Or Are They On The ‘Sell’ List?
In the last year, many have taken an interest in biotech penny stocks. A significant driving factor of this was that many of these corporations shifted focus to creating a vaccine for the COVID-19 pandemic. This helped some biotech penny stocks reach new heights in the market. These types of stocks tend to be more volatile. With biotech companies, these assets are among the most volatile in the market, in general.
There are a few things that can impact the price of biotech stocks that are important to note. These are things that investors should always have an eye on if investing in penny stocks. Biotechnology companies are constantly participating in industry conferences to provide updates or an outlook.
In addition to this, like many other companies, financial results and corporate updates will come out every so often as well. If large established corporations are only administering the current vaccines, why are investors interested in pharmaceutical penny stocks?
Vaccines are not the most significant driving factor of market momentum. However, these vaccine stocks had shown investors the potential of biotech penny stocks as a whole. These piqued investor interest and have now grown in popularity quite a bit. This has resulted in lots of new names to watch. Some think that the market for biotech penny stocks could continue to grow for years.
A report by Grand View Research stated that the global biotech market is estimated to have a compound annual growth rate of 15.83% in the next 7 or 8 years. As approval processes improve and research and advancements are happening all the time, there are plenty of biotech penny stocks to watch. Here are 4 trending in the stock market today.
Top Biotech Penny Stocks To Watch
- Hepion Pharmaceuticals Inc. (NASDAQ: HEPA)
- Seneca Biopharma Inc. (NASDAQ: SNCA)
- Dare Bioscience Inc. (NASDAQ: DARE)
- Conformis Inc. (NASDAQ: CFMS)
Hepion Pharmaceuticals Inc.
After increasing nearly 31% in the last 5 days, many investors have their eyes on Hepion Pharmaceuticals Inc. Hepion is a biopharmaceutical company that develops pleiotropic drug therapy for treating chronic liver diseases. One of its main products is CRV431, which is a cyclophilin inhibitor.
On February 18th, Hepion announced the closure of a public offering of 44,200,000 shares of common stock. The offering price was $2 a share. This will result in gross proceeds of $88,400,000 before discounts and expenses. The proceeds will be used for research and development, as well as working capital and corporate purposes.
While this sent the stock lower in the short-term at the end of February, March has been a different story. This week, HEPA stock surged thanks to the news on a presentation being made this weekend at the NASH-TAG 2021 Conference.
Hepion’s CEO, Dr. Robert Foster, explained, “In this, the first public oral presentation of the top-line data from the low dose cohort in the ‘AMBITION’ Phase 2a study, we are excited to share both our findings and to highlight the clinical trial risk mitigation potential of AI-POWR as we plan for the initiation of our Phase 2b study.”
Seneca Biopharma Inc.
Another biotech penny stock that has been making the rounds is Seneca Biopharma Inc., a clinical-stage biopharmaceutical company. It researches and develops nervous system therapies based on proprietary human neuronal stem cells and molecules. One of its more recent data pieces was released on January 20th.
The company announced top-line data from phase 2 clinical studies in China. These studies are for the treatment of Ischemic stroke. The study had 23 patients that were assigned to treatment or placebo arms. One of the leading causes of death in China is stokes so this research can be significant. The former President of BaYi Brian Hospital, Ruxiang Xu, said, “Results from this study show NSI-566 may have utility as a treatment for paralysis and motor deficits caused by ischemic stroke. Additional larger studies will be critical in demonstrating the clinical potential of NSI-566 in this unmet need.”
However, right now, traders are still focusing on the outcome of its pending merger with Leading BioSciences. The two announced a merger agreement late last year in which the combined companies will develop Leading’s GI treatment candidate, LB1148. A name and symbol change will follow; Palisade Bio under ticker PALI.
Daré Bioscience Inc.
This next biotech penny stock to watch has been a big gainer in the market this week. Daré Bioscience Inc. focuses on the development and marketing of products for women’s health. The US-based company’s pipeline includes therapies for contraception, fertility, sexual, and personal health.
Daré has been participating in a variety of virtual conferences to get its information out to the public. Back in December, the company released positive topline results from DARE-BVFREE. This is a phase 3 trial that the company has been working on for a while.
This month, the company participated at H.C. Wainwright’s Global Life Sciences Conference. Chief Executive Officer Sabrina Martucci Johnson participated in a panel discussion titled “Women’s Health Companies Blazing the Trail.” This is 1 of many upcoming conferences that the company will attend.
- 5 Reddit Penny Stocks Heating Up Small Caps Today
- 4 Penny Stocks Analysts Say To Buy With Targets Of Up To 360%
Next week, Daré presents at M Vest and Maxim Group’s Inaugural Emerging Growth Conference. Following that, the company will be at the BIO-Europe Spring Digital conference from the 22nd to March 25th. It will be interesting to see how traders respond to what Daré has to say about its current and future plans.
Conformis Inc. is a medical tech company developing, manufacturing, and selling joint replacement implants. These include products such as knee replacements, cruciate-retaining products, and other ligament substitution products.
This healthcare penny stock to watch should be performing poorly as it just reported a fourth-quarter loss and missed revenue estimates. Its revenue decreased 16% year over year, and its gross margin was 47%, a decrease of 180 basis points year over year. This did cause CFMS stock price to fall. But now, CFMS stock is already moving back up.
But as we say, it’s essential to see what management has to say when it comes to biotech earnings. “We expect 2021 to be an exciting year in regards to new product offerings, especially our new total knee system. While this system can be used in the in-patient and out-patient settings, we are particularly focused on the ambulatory care setting,” said Mark Augusti, President, and Chief Executive Officer. “Our recently completed $85 million capital raise gives us the flexibility to drive our growth strategy.”
As you’ll see, since the beginning of the week, CFMS stock has reversed course. Heading into next week, shares have broken back above the $1 level for the first time since March 4th.
The post 4 Biotech Penny Stocks To Watch Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.nasdaq stocks pandemic covid-19 penny stocks vaccine treatment therapy epicenter mitigation small caps europe china
Las Vegas Strip faces growing bed bug problem
With huge events including Formula 1, CES, and the Super Bowl looming, the Las Vegas Strip faces an issue that could be a major cause for concern.
Las Vegas beat the covid pandemic.
It wasn't that long ago when the Las Vegas Strip went dark and people questioned whether Caesars Entertainment, MGM Resorts International, Wynn Resorts, and other Strip players would emerge from the crisis intact.
In the darkest days, the entire Las Vegas Strip was closed down and when it reopened, it was not business as usual. Caesars Entertainment (CZR) - Get Free Report and MGM reopened slowly with all sorts of government-mandated restrictions in place.
The first months of the Strip's comeback featured temperature checks, a lot of plexiglass, gaming tables with limited numbers of players, masks, and social distancing. It was an odd mix of celebration and restraint as people were happy to be in Las Vegas, but the Strip was oddly empty, some casinos remained closed, and gaming floors were sparsely filled.
When vaccines became available, the Las Vegas Strip benefitted quickly. Business and international travelers were slow to return, but leisure travelers began bringing crowds back to pre-pandemic levels.
The comeback, however, was very fragile. CES 2022 was supposed to be Las Vegas's return to normal, the first major convention since covid. In reality, surging cases of the covid omicron variant caused most major companies to pull out.
Even with vaccines and covid tests required, an event that was supposed to be close to normal, ended up with 25% of 2020's pre-covid attendance. That CES showed just how quickly public sentiment — not actual danger — can ruin an event in Las Vegas.
Now, with November's Formula 1 Race, CES in January, and the Super Bowl in February all slated for Las Vegas, a rising health crisis threatens all of those events.
The Arena Media Brands, LLC and respective content providers to this website may receive compensation for some links to products and services on this website.
The Las Vegas Strip has a bed bug problem
While bed bugs may not be as dangerous as covid, Respiratory Syncytial Virus (RSV), Legionnaires’ disease, and some of the other infectious diseases that the Las Vegas Strip has faced over the past few years, they're still problematic. Bed bugs spread easily and a small infestation can become a large one quickly.
The sores caused by bed bugs are also a social media nightmare for the Las Vegas Strip. If even a few Las Vegas Strip visitors wake up covered in bed bug bites, that could become a viral nightmare for the entire city.
In late-August, reports came out the bed bugs had been at seven Las Vegas hotel, mostly on the Strip over the past two years. The impacted properties includes Caesars Planet Hollywood and Caesars Palace as well as MGM Resort International's (MGM) - Get Free Report MGM Grand, and others including Circus Circus, The Palazzo, Tropicana, and Sahara.
"Now, that number is nine with the addition of The Venetian and Park MGM. According to the health department report, a Venetian guest reported seeing the bloodsuckers on July 29 and was moved to another room. An inspection three days later confirmed their presence," Casino.org reported.
The Park MGM bed bug incident took place on Aug. 14.
Bed bugs remain a Las Vegas Strip problem
Only Tropicana, which is soon going to be demolished, and Sahara, responded to Casino.org about their bed bug issues. Caesars and MGM have not commented publicly or responded to requests from KLAS or Casino.org.
That makes sense because the resorts do not want news to spread about potential bed bug problems when the actual incidents have so far been minimal. The problem is that unreported bed bug issues can rapidly snowball.
The Environmental Protection Agency (EPA) shares some guidelines on bed bug bites on its website that hint at the depth of the problem facing Las Vegas Strip resorts.
"Regularly wash and heat-dry your bed sheets, blankets, bedspreads and any clothing that touches the floor. This reduces the number of bed bugs. Bed bugs and their eggs can hide in laundry containers/hampers. Remember to clean them when you do the laundry," the agency shared.
Normally, that would not be an issue in Las Vegas as rooms are cleaned daily. Since the covid pandemic, however, some people have opted out of daily cleaning and some resorts have encouraged that.
Not having daily room cleaning in just a few rooms could lead to quick spread.
"Bed bugs spread so easily and so quickly, that the University of Kentucky's entomology department notes that "it often seems that bed bugs arise from nowhere."
"Once bed bugs are introduced, they can crawl from room to room, or floor to floor via cracks and openings in walls, floors and ceilings," warned the University's researchers.
spread social distancing pandemic
Americans are having a tough time repaying pandemic-era loans received with inflated credit scores
Borrowers are realizing the responsibility of new debts too late.
With the economy of the United States at a standstill during the Covid-19 pandemic, the efforts to stimulate the economy brought many opportunities to people who may have not had them otherwise.
However, the extension of these opportunities to those who took advantage of the times has had its consequences.
A report by the Financial Times states that borrowers in the United States that took advantage of lending opportunities during the Covid-19 pandemic are falling behind on actually paying back their debt.
At a time when stimulus checks were handed out and loan repayments were frozen to help those affected by the economic shock of Covid-19, many consumers in the States saw that lenders became more willing to provide consumer credit.
According to a report by credit reporting agency TransUnion, the median consumer credit score jumped 20% to a peak of 676 in the first quarter of 2021, allowing many to finally have “good” credit scores. However, their data also showed that those who took out loans and credit from 2021 to early 2023 are having an hard time managing these debts.
“Consumer finance companies used this opportunity to juice up their growth at a time when funding was ample and consumers’ finances had gotten an artificial boost,” Chief economist of Moody’s Analytics Mark Zandi told FT. “Certainly a lot of lower-income households that got caught up in all of this will feel financial pain.”
Moody’s data shows that new credit cards accounts that were opened in the first quarter of 2023 have a 4% delinquency rate, while the same rate in September 2022 was 4.5%. According to the analysts, these levels were the highest for the same point of the year since 2008.
Additionally, a study by credit scoring company VantageScore found that credit cards issued in March 2022 had higher delinquency rates than cards issued at the same time during the prior four years.
- Why the recession never really hit -- and what indicates that it still could
- Jim Cramer and Dan Ives say a powerful technology will give the markets a boost
- Here's what companies Nvidia is joining in the $1 Trillion market cap club
Credit cards were not the only debts that American consumers took on. As per S&P Global Ratings data, riskier car loans taken on during the height of the pandemic have more repayment problems than in previous years. In 2022, subprime borrowers were becoming delinquent on new cars loans at twice the rate of pre-pandemic levels.
S&P auto loan tracker Amy Martin told FT that lenders during the pandemic were “rather aggressive” in terms of signing new loans.
Bill Moreland of research group BankRegData has warned about these rising delinquencies in the past and had recently estimated that by late 2022, there were hundreds of billions of dollars in what he calls “excess lending based upon artificially inflated credit scores”.
The Government's Role
Because so many are failing to pay their bills, many are wary that the government assistance may have been a financial double-edged sword; as they were meant to alleviate financial stress during lockdown, while it led some of them to financial difficulty.
The $2.2 trillion Cares Act federal aid package passed in the early stages of the pandemic not only put cash in the American consumer’s pocket, but also protected borrowers from foreclosure, default and in some instances, lenders were barred from reporting late payments to credit bureaus.
Yeshiva University law professor Pam Foohey specializes in consumer bankruptcy and believes that the Cares Act was good policy, however she shifts the blame away from the consumers and borrowers.
“I fault lenders and the market structure for not having a longer-term perspective. That’s not something that the Cares Act should have solved and it still exists and still needs to be addressed.”
Get exclusive access to portfolio managers and their proven investing strategies with Real Money Pro. Get started now.recession economic shock bankruptcy foreclosure default stimulus trump lockdown stay-at-home orders pandemic coronavirus covid-19 recession stimulus russia
Inflation: raising interest rates was never the right medicine – here’s why central bankers did it anyway
We need to start cutting rates, but there’s something that has to happen first.
Inflation remains too high in the UK. The annual rate of consumer price inflation to September was 6.7%, the same as a month earlier. This is well below the 11.1% peak reached in October 2022, but the failure of inflation to keep falling indicates it is proving far more stubborn than anticipated.
This may prompt the Bank of England’s Monetary Policy Committee (MPC) to raise the benchmark interest rate yet again when it meets in November, but in my view this would not be entirely justified.
In reality, the rate hikes that began two years ago have not been very helpful in tackling inflation, at least not directly. So what’s the problem and is there a better alternative?
Right policy, wrong inflation
Raising interest rates is the MPC’s main tool for trying to get inflation back to its target rate of 2%. The idea is that this makes it more expensive to borrow money, which should reduce consumer demand for goods and services.
The trouble is that the type of inflation recently witnessed in the UK seems less a problem of excessive demand than because costs have been rising for manufacturers and service providers. It’s known as “cost-push inflation” as opposed to “demand-pull inflation”.
Inflation rates (UK, US, eurozone)
Production costs have risen for several reasons. During the COVID-19 pandemic, central banks “created money” through quantitative easing to enable their governments to run large spending deficits to pay for furloughs and other interventions to help citizens through the crisis.
When countries started reopening, it meant people had money in their pockets to buy more goods and services. Yet with China still in lockdown, global supply chains could not keep pace with the resurgent demand so prices went up – most notably oil.
Oil price (Brent crude, US$)
Then came the Ukraine war, which further drove up prices of fundamental commodities, such as energy. This made inflation much worse than it would otherwise have been. You can see this reflected in consumer price inflation (CPI): it was just 0.6% in the year to June 2020, then rose to 2.5% in the year to June 2021, reflecting the supply constraints at the end of lockdown. By June 2022, four months after Russia’s invasion of Ukraine, CPI was 9.4%.
The policy problem
This begs the question, why has the Bank of England (BoE) been raising rates if it’s unlikely to be effective? One answer is that other central banks have been raising rates. If the BoE doesn’t mirror rate rises in the US and eurozone, investors in the UK may move their money to these other areas because they’ll get better returns on bonds. This would see the pound depreciating against the US dollar and euro, in turn increasing import prices and aggravating inflation.
Part of the problem has been that the US has arguably faced more of the sort of demand-led inflation against which interest rates are effective. For one thing, the US has been less at the mercy of rising energy prices because it is energy self-sufficient. It also didn’t lock down as uniformly as other major economies during the pandemic, so had a little more space to grow.
At the same time, the US has been more effective at bringing down inflation than the UK, which again suggests it was fighting demand-driven price rises. In other words, the UK and other countries may to some extent have been forced to follow suit with raising interest rates to protect their currencies, not to fight inflation.
How harmful have the rate rises been in the UK? They have not brought about a recession yet, but growth remains very weak. Lots of people are struggling with the cost of living, as well as rent or mortgage costs. Several million people are due to be hit by much higher mortgage rates as their fixed-rate deals end between now and the end of 2024.
UK GDP growth (%)
If hiking interest rates is not really helping to curb inflation, it makes sense to start moving in the opposite direction before the economic situation gets any worse. To avoid any damage to the pound, the answer is for the leading central banks to coordinate their policies so that they cut rates in lockstep.
Unless and until this happens, there would seem to be no quick fix available. One piece of good news is that the energy price cap for typical domestic consumption was reduced from October 1 from £1,976 to £1,834 a year. That 7% reduction should lead to consumer price inflation coming down significantly towards the end of 2023.
More generally, the Bank of England may simply have to hope that world events move inflation in the desired direction. A key question is going to be whether the wars in Ukraine and Israel/Gaza result in further cost pressures.
Unfortunately there is a precedent for a Middle East conflict leading to a global economic crisis: following the joint assault on Israel by Syria and Egypt in 1973, Israel’s retaliation prompted petroleum cartel OPEC to impose an oil embargo. This led to an almost fourfold increase in the price of crude oil.
Since oil was fundamental to the costs of production, inflation in the UK rose to over 16% in 1974. There followed high unemployment, resulting in an unwelcome combination that economists referred to as stagflation.
These days, global production is in fact less reliant on oil as renewables have become a growing part of the energy mix. Nonetheless, an oil price hike would still drive inflation higher and weaken economic growth. So if the Middle East crisis does spiral, we may be stuck with stubborn, untreatable inflation for even longer.
Robert Gausden does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.recession unemployment economic growth reopening bonds monetary policy mortgage rates currencies pound us dollar euro governor lockdown pandemic covid-19 recession gdp interest rates commodities oil uk russia ukraine china
Uncategorized9 hours ago
Thai crypto investors turn to tarot cards, divine signals to predict market
Uncategorized14 hours ago
Massive consumer brand, Johnson & Johnson pursues bankruptcy filing
Uncategorized13 hours ago
Jeff Bezos and Bill Gates-backed billion dollar business closes
Uncategorized13 hours ago
Bearish Triad: Stock Market Indexes and Market Breadth Test Important Support Level; VIX Above 20
Uncategorized13 hours ago
Should We Use Weakness To Accumulate NVDA Before Its Next Launch?
Uncategorized11 hours ago
Dave Ramsey explains how budgeting is a ‘key to financial peace’
Uncategorized15 hours ago
Sam Bankman-Fried trial moves to final stages
Uncategorized14 hours ago
Morgan Stanley believes crypto winter is over, Bitcoin halving will kick off new bull run